From: Novel biomarkers assist in detection of liver fibrosis in HCV patients
Factor | Liver biopsy | Serum markers |
---|---|---|
Cost | Expensive | Laboratory cost |
Risks | Significant | Minimal |
Contraindications | Multiple: bleeding diathesis, morbid obesity, ascites, extrahepatic biliary obstruction | Conditions with a high rate of false positivity |
Accuracy | 80% | 60–80% |
System requirements | Operator, pathology laboratory, pathologist | Clinical laboratory, phlebotomy, materials. |
Specimen adequacy | Length of the liver fragment at least 15 mm with 6–8 portal tracts | Blood sample |
False positives | Interobserver variability | Sepsis, nonhepatic inflammation, hemolysis, trombocitopenia |
False negatives | Sampling variability | Varies per test |
Time for results | 24–72 h minimum | 1–2 h minimum |